502 results
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
7 May 24
Ligand Reports First Quarter 2024 Financial Results
4:03pm
such obligations; changes in
general economic conditions, including as a result of war, conflict or epidemic diseases and ongoing or future litigation … Securities Litigation Reform Act of 1995.
Other Disclaimers and Trademarks
The information in this press release regarding certain third-party
8-K
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
7 May 24
Entry into a Material Definitive Agreement
7:36am
license fees and milestone revenues we may receive. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act
8-K
EX-99.1
r48r5jdxmdsvaks3v
27 Feb 24
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
7:24am
8-K
ahmyjx mbd8iuw3nlkrl
5 Jan 24
Other Events
5:50pm
8-K
r8xl60 5lt1wt9
1 Dec 23
Entry into a Material Definitive Agreement
8:25am
8-K/A
EX-99.1
4si9kkpg dvhzx4o53e9
9 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
9:48pm
8-K
EX-99.1
x3nb2u9of31619bu0
8 Nov 23
Ligand Reports Third Quarter 2023 Financial Results
4:08pm
8-K
1bdv3l07txjkr704ctk
18 Oct 23
Other Events
9:03am
8-K
EX-10.1
cqoo82waqw 2h
17 Oct 23
Entry into a Material Definitive Agreement
7:24pm
8-K
dd7in
18 Sep 23
Other Events
5:26pm
8-K
EX-99.1
zjwwprac48ibq5
8 Aug 23
Ligand Reports Second Quarter 2023 Financial Results
4:02pm
8-K
EX-99.1
0tfmf mo4wzhndstb
4 May 23
Ligand Reports First Quarter 2023 Financial Results
4:06pm